K160252 is an FDA 510(k) clearance for the OmniPod Insulin Management System. Classified as Pump, Infusion, Insulin (product code LZG), Class II - Special Controls.
Submitted by Insulet Corporation (Billerica, US). The FDA issued a Cleared decision on April 27, 2016 after a review of 86 days - a notably fast clearance cycle.
This device falls under the General Hospital FDA review panel, regulated under 21 CFR 880.5725 - the FDA general hospital device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.
Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.
View all Insulet Corporation devices